Stated preferences for human papillomavirus vaccination for adolescents in selected communities in Ibadan, Southwest Nigeria: A discrete choice experiment

References

• Pimple SA, Mishra GA. Global strategies for cervical cancer prevention and screening. Minerva Ginecol. 2019;71(4):1–8. doi:10.23736/S0026-4784.19.04397-1.
   PubMed Web of Science ®Google Scholar
• Canfell K. Towards the global elimination of cervical cancer. Papillomavirus Res (Amsterdam, Netherlands). 2019;8:100170. doi:10.1016/j.pvr.2019.100170.
   PubMed Web of Science ®Google Scholar
• United States Food and Drug Administration. FDA approves Gardasil 9 for prevention of certain cancers caused by five additional types of HPV. FDA News Release; 2014.
   Google Scholar
• Canepa P, Orsi A, Martini M, Icardi G. HPV related diseases in males: a heavy vaccine-preventable burden. J Prev Med Hyg. 2013;54:61–70.
   PubMedGoogle Scholar
• Lowy DR, Schiller JT. Reducing HPV-associated cancer globally. Cancer Prev Res (Philadelphia, Pa). 2012;5(1):18–23. doi:10.1158/1940-6207.CAPR-11-0542.
   PubMed Web of Science ®Google Scholar
• Adewole IF, Benedet JL, Crain BT, Follen M. Evolving a strategic approach to cervical cancer control in Africa. Gynecol Oncol. 2005;99(3):S209–S12. doi:10.1016/j.ygyno.2005.07.086.
   PubMed Web of Science ®Google Scholar
• Bello FA, Enabor OO, Adewole IF. Human papilloma virus vaccination for control of cervical cancer: a challenge for developing countries. Afr J Reprod Health. 2011;15:25–30.
   PubMedGoogle Scholar
• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: gLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492.
   PubMed Web of Science ®Google Scholar
• Bruni L, Diaz M, Barrionuevo-Rosas L, Herrero R, Bray F, Bosch FX, de Sanjosé S, Castellsagué X. Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis. Lancet Glob Health. 2016;4(7):e453–e63. doi:10.1016/S2214-109X(16)30099-7.
   PubMed Web of Science ®Google Scholar
• Sundström K, Elfström KM. Advances in cervical cancer prevention: efficacy, effectiveness, elimination? PLoS Med. 2020;17(1): e1003035-e. doi:10.1371/journal.pmed.1003035.
   PubMed Web of Science ®Google Scholar
• PATH. Global HPV vaccine introduction overview: global national HPV vaccine introduction maps; 2021.
   Google Scholar
• Ezeanochie MC, Olagbuji BN. Human papilloma virus vaccine: determinants of acceptability by mothers for adolescents in Nigeria. Afr J Reprod Health. 2014;18:154–58.
   PubMed Web of Science ®Google Scholar
• Umeh IB, Nduka SO, Ekwunife OI. Mothers’ willingness to pay for HPV vaccines in Anambra state, Nigeria: a cross sectional contingent valuation study. Cost Eff Resour Alloc. 2016;14(1):8. doi:10.1186/s12962-016-0057-0.
   PubMedGoogle Scholar
• Omondi-Ogutu M, Imunya JM. Parental acceptance of human papillomavirus vaccine for their pre-pubertal and teenage daughters. East Afr Med J. 2011;88:163–70.
   Google Scholar
• Ugwu EO, Obi SN, Ezechukwu PC, Okafor II, Ugwu AO. Acceptability of human papilloma virus vaccine and cervical cancer screening among female health-care workers in Enugu, Southeast Nigeria. Niger J Clin Pract. 2013;16(2):249–52. doi:10.4103/1119-3077.110141.
   PubMed Web of Science ®Google Scholar
• Poole DN, Tracy JK, Levitz L, Rochas M, Sangare K, Yekta S, Tounkara K, Aboubacar B, Koita O, Lurie M, et al. A cross-sectional study to assess HPV knowledge and HPV vaccine acceptability in Mali. PloS One. 2013;8(2):e56402. doi:10.1371/journal.pone.0056402.
   PubMed Web of Science ®Google Scholar
• Balogun F, Omotade O, Maree J. “She must have been sleeping around”: contextual interpretations of cervical cancer and views regarding HPV vaccination for adolescents in selected communities in Ibadan, Nigeria. PloS One. 2018;13(9):e0203950. doi:10.1371/journal.pone.0203950.
   PubMed Web of Science ®Google Scholar
• Vermandere H, Naanyu V, Mabeya H, Vanden Broeck D, Michielsen K, Degomme O, Consolaro MEL. Determinants of acceptance and subsequent uptake of the HPV vaccine in a cohort in Eldoret, Kenya. PloS One. 2014;9(10):e109353. doi:10.1371/journal.pone.0109353.
   PubMed Web of Science ®Google Scholar
• Turiho AK, Okello ES, Muhwezi WW, Katahoire AR. Perceptions of human papillomavirus vaccination of adolescent schoolgirls in western Uganda and their implications for acceptability of HPV vaccination: a qualitative study. BMC Res Notes. 2017;10(1):431. doi:10.1186/s13104-017-2749-8.
   PubMedGoogle Scholar
• Dempsey AF, Patel DA. HPV vaccine acceptance, utilization and expected impacts in the US. Hum Vaccin. 2010;6(9):715–20. doi:10.4161/hv.6.9.12730.
   PubMed Web of Science ®Google Scholar
• Reed Johnson F, Lancsar E, Marshall D, Kilambi V, Mühlbacher A, Regier DA, Bresnahan BW, Kanninen B, Bridges JFP. Constructing experimental designs for discrete-choice experiments: report of the ISPOR conjoint analysis experimental design good research practices task force. Value Health. 2013;16(1):3–13. doi:10.1016/j.jval.2012.08.2223.
   PubMed Web of Science ®Google Scholar
• Thurstone LL. The method of paired comparisons for social values. J Abnorm Soc Psychol. 1927;21(4):384–400. doi:10.1037/h0065439.
   Google Scholar
• McFadden D. Conditional logit analysis of qualitative choice behavior. In: Zarembka P editor. Frontiers in econometrics. University of California , CA: Academic Press; 1974. p. 105–42.
   Google Scholar
• Kish L. Survey sampling. New York: John Wiley and Sons, Inc.; 1965.
   Google Scholar
• Ibadan north local government area in Nigeria. https://www.citypopulation.de/
   Google Scholar
• Goncalves AK, Cobucci RN, Rodrigues HM, de Melo AG, Giraldo PC. Safety, tolerability and side effects of human papillomavirus vaccines: a systematic quantitative review. Braz J Infect Dis. 2014;18(6):651–59. doi:10.1016/j.bjid.2014.02.005.
   PubMed Web of Science ®Google Scholar
• Meites E, Kempe A, Markowitz LE. Use of a 2-dose schedule for human papillomavirus vaccination — updated recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep. 2016;65(49):1405–08. doi:10.15585/mmwr.mm6549a5.
   PubMed Web of Science ®Google Scholar
• Hole A. DCREATE: stata module to create efficient designs for discrete choice experiments; 2017.
   Google Scholar
• van den Broek-Altenburg E, Atherly A. Using discrete choice experiments to measure preferences for hard to observe choice attributes to inform health policy decisions. Health Econ Rev. 2020;10(1):18. doi:10.1186/s13561-020-00276-x.
   PubMed Web of Science ®Google Scholar
• Oyedeji G. Socioeconomic and cultural background of hospitalised children in Ilesa. Nig J Paed. 1985;12:111–17.
   Google Scholar
• Lancsar E, Fiebig DG, Hole AR. Discrete choice experiments: a guide to model specification, estimation and software. PharmacoEconomics. 2017;35(7):697–716. doi:10.1007/s40273-017-0506-4.
   PubMed Web of Science ®Google Scholar
• Ngorsuraches S, Nawanukool K, Petcharamanee K, Poopantrakool U. Parents’ preferences and willingness-to-pay for human papilloma virus vaccines in Thailand. J Pharm Policy Pract. 2015;8(1):20. doi:10.1186/s40545-015-0040-8.
   PubMedGoogle Scholar
• Poulos C, Yang JC, Levin C, Van Minh H, Giang KB, Nguyen D. Mothers’ preferences and willingness to pay for HPV vaccines in Vinh Long Province, Vietnam. Soc Sci Med (1982). 2011;73(2):226–34. doi:10.1016/j.socscimed.2011.05.029.
   PubMed Web of Science ®Google Scholar
• Ogilvie G, Anderson M, Marra F, McNeil S, Pielak K, Dawar M, McIvor M, Ehlen T, Dobson S, Money D, et al. A population-based evaluation of a publicly funded, school-based HPV vaccine program in British Columbia, Canada: parental factors associated with HPV vaccine receipt. PLoS Med. 2010;7(5):e1000270. doi:10.1371/journal.pmed.1000270.
   PubMed Web of Science ®Google Scholar
• Drolet M, Benard E, Perez N, Brisson M, Ali H, Boily M-C, Baldo V, Brassard P, Brotherton JML, Callander D. Population-Level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. Lancet (London, England). 2019;394(10197):497–509. doi:10.1016/S0140-6736(19)30298-3.
   PubMed Web of Science ®Google Scholar
• Garland SM, Kjaer SK, Munoz N, Block SL, Brown DR, DiNubile MJ, Lindsay BR, Kuter BJ, Perez G, Dominiak-Felden G, et al. Impact and effectiveness of the quadrivalent human papillomavirus vaccine: a systematic review of 10 years of real-world experience. Clin Infect Dis. 2016;63(4):519–27. doi:10.1093/cid/ciw354.
   PubMed Web of Science ®Google Scholar
• Bhatla N, Nene BM, Joshi S, Esmy PO, Poli URR, Joshi G, Verma Y, Zomawia E, Pimple S, Prabhu PR, et al. Are two doses of human papillomavirus vaccine sufficient for girls aged 15–18 years? Results from a cohort study in India. Papillomavirus Res (Amsterdam, Netherlands). 2018;5:163–71. doi:10.1016/j.pvr.2018.03.008.
   PubMed Web of Science ®Google Scholar
• Kreimer AR, Struyf F, Del Rosario-Raymundo MR, Hildesheim A, Skinner SR, Wacholder S, Garland SM, Herrero R, David M-P, Wheeler CM, et al. Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica vaccine and PATRICIA trials. Lancet Oncol. 2015;16(7):775–86. doi:10.1016/S1470-2045(15)00047-9.
   PubMed Web of Science ®Google Scholar
• Hariri S, Bennett NM, Niccolai LM, Schafer S, Park IU, Bloch KC, Unger ER, Whitney E, Julian P, Scahill MW, et al. Reduction in HPV 16/18-associated high grade cervical lesions following HPV vaccine introduction in the United States – 2008–2012. Vaccine. 2015;33(13):1608–13. doi:10.1016/j.vaccine.2015.01.084.
   PubMed Web of Science ®Google Scholar
• Head KJ, Biederman E, Sturm LA, Zimet GD. A retrospective and prospective look at strategies to increase adolescent HPV vaccine uptake in the United States. Hum Vaccin Immunother. 2018;14(7):1626–35. doi:10.1080/21645515.2018.1430539.
   PubMed Web of Science ®Google Scholar
• Burger EA, Campos NG, Sy S, Regan C, Kim JJ. Health and economic benefits of single-dose HPV vaccination in a Gavi-eligible country. Vaccine. 2018;36(32):4823–29. doi:10.1016/j.vaccine.2018.04.061.
   PubMed Web of Science ®Google Scholar
• Wong CKH, Man KKC, Ip P, Kwan M, McGhee SM. Mothers’ preferences and willingness to pay for human papillomavirus vaccination for their daughters: a discrete choice experiment in Hong Kong. Value Health. 2018;21(5):622–29. doi:10.1016/j.jval.2017.10.012.
   PubMed Web of Science ®Google Scholar
• Wilson R. HPV vaccine acceptance in West Africa: a systematic literature review. Vaccine. 2021;39(37):5277–84. doi:10.1016/j.vaccine.2021.06.074.
   PubMed Web of Science ®Google Scholar
• Okedo-Alex IN, Akamike IC, Ezeanosike OB, Uneke CJ. A review of the incidence and determinants of catastrophic health expenditure in Nigeria: implications for universal health coverage. Int J Health Plann Manage. 2019;34(4). doi:10.1002/hpm.2847.
   Web of Science ®Google Scholar
• Kwan TT, Chan KK, Yip AM, Tam KF, Cheung AN, Young PM, Lee PWH, Ngan HYS. Barriers and facilitators to human papillomavirus vaccination among Chinese adolescent girls in Hong Kong: a qualitative-quantitative study. Sex Transm Infect. 2008;84(3):227–32. doi:10.1136/sti.2007.029363.
   PubMed Web of Science ®Google Scholar
• Fernandes R, Potter BK, Little J. Attitudes of undergraduate university women towards HPV vaccination: a cross-sectional study in Ottawa, Canada. BMC Womens Health. 2018;18(1):134. doi:10.1186/s12905-018-0622-0.
   PubMedGoogle Scholar
• Jit M, Choi YH, Edmunds WJ. Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ (Clinical Research Ed). 2008;337(jul17 2):a769. doi:10.1136/bmj.a769.
   PubMedGoogle Scholar
• Head KJ, Cohen EL. Young women’s perspectives on cervical cancer prevention in Appalachian Kentucky. Qual Health Res. 2011;22(4):476–87. doi:10.1177/1049732311425053.
   PubMed Web of Science ®Google Scholar
• Hanson CM, Eckert L, Bloem P, Cernuschi T. Gavi HPV programs: application to implementation. Vaccines. 2015;3(2):408–19. doi:10.3390/vaccines3020408.
   Google Scholar
• Marlow LA, Waller J, Wardle J. Trust and experience as predictors of HPV vaccine acceptance. Hum Vaccin. 2007;3(5):171–75. doi:10.4161/hv.3.5.4310.
   PubMed Web of Science ®Google Scholar
• Owoaje E, Rahimi AO, Kalbarczyk A, Akinyemi O, Peters MA, Alonge OO. Conflict, community, and collaboration: shared implementation barriers and strategies in two polio endemic countries. BMC Public Health. 2020;20(S4):1178. doi:10.1186/s12889-020-09235-x.
   PubMedGoogle Scholar
• Vercruysse J, Chigurupati NL, Fung L, Apte G, Pierre-Joseph N, Perkins RB. Parents’ and providers’ attitudes toward school-located provision and school-entry requirements for HPV vaccines. Human Vaccines & Immunotherapeutics. 2016;12(6):1606–14. doi:10.1080/21645515.2016.1140289.
   PubMed Web of Science ®Google Scholar
• Lefevere E, Theeten H, Hens N, De Smet F, Top G, Van Damme P. From non school-based, co-payment to school-based, free human papillomavirus vaccination in Flanders (Belgium): a retrospective cohort study describing vaccination coverage, age-specific coverage and socio-economic inequalities. Vaccine. 2015;33(39):5188–95. doi:10.1016/j.vaccine.2015.07.088.
   PubMed Web of Science ®Google Scholar
• Cadeddu C, Castagna C, Sapienza M, Lanza TE, Messina R, Chiavarini M, Ricciardi W, de Waure C. Understanding the determinants of vaccine hesitancy and vaccine confidence among adolescents: a systematic review. Hum Vaccin Immunother. 2021;17(11):4470–86. doi:10.1080/21645515.2021.1961466.
   PubMed Web of Science ®Google Scholar
• Perez S, Zimet GD, Tatar O, Stupiansky NW, Fisher WA, Rosberger Z. Human papillomavirus vaccines: successes and future challenges. Drugs. 2018;78(14):1385–96. doi:10.1007/s40265-018-0975-6.
   PubMed Web of Science ®Google Scholar
• Middleman A. School-Located vaccination for adolescents: past, present, and future and implications for HPV vaccine delivery. Hum Vaccin Immunother. 2016;12(6):1599–605. doi:10.1080/21645515.2016.1168953.
   PubMed Web of Science ®Google Scholar